Earlier this year, the American Urological Association, in collaboration with the Society of Urologic Oncology, approved the updated 2023 Advanced Prostate Cancer Guideline, providing new guidance around the prognosis and treatment of advanced disease. This guideline will help urologists keep up-to-date on evolving protocols and advancements in treatment for patients with prostate cancer.
The guideline recommendations focus on offering androgen deprivation therapy (ADT) in combination with either androgen pathway-directed therapy or chemotherapy and does not include recommendations on using ADT monotherapy for patients with metastatic castration-sensitive prostate cancer.
To learn more about the updated guideline, visit: [ Ссылка ]
*Content is not certified for continuing education credits.
